ENHANCED LIVER FIBROSIS

PARTICIPATE IN THE NASH STUDY

Join Today

ENHANCED LIVER FIBROSIS (ELF)

The voluntary ELF test is a routine blood test that provides an ELF score that delivers information on liver fibrosis severity. The results of this diagnostic test will be uploaded into the participant’s medical record. Along with other medical information, this test can be used to inform participants and their physicians about their risk of developing liver disease and liver related outcomes.

More information about this test can be found here.

IMPORTANT INFORMATION TO CONSIDER PRIOR TO HAVING YOUR ELF TEST COMPLETED
BIOTIN (VITAMIN B7):
Patients in consultation with their clinician should discontinue taking any preparation containing biotin, for example multivitamins containing biotin (vitamin B7), hair, skin, and nail supplements containing biotin, and foods or beverages supplements with biotin for 3 days prior to the blood collection. Patients with impaired renal function should discontinue biotin use 4 days before collection.

NO FASTING REQUIRED:
This blood draw does not require participants to fast prior to collection.

RETURN OF RESULTS
Once your blood sample has been collected, your results will be posted to your Renown MyChart in approximately 2-3 weeks. Your results will also be accessible in your medical record for your healthcare providers to review. Please contact your Primary Care Provider (PCP) or our research team if you have any questions or concerns about your results.

Renown IHI has begun enrollment for the Nonalcoholic Steatohepatitis Liver Disease Genome Atlas study and is currently available online to Renown patients who have already participated or are new to the Healthy Nevada Project.

Join The STUDY
Further Information

  • The voluntary ELF test is a routine blood test that provides an ELF score that delivers information on liver fibrosis severity. 
  • The ELF test is performed by Siemens Healthcare Laboratory (Siemens) based in Berkeley, CA, which is a CAP accredited high complexity CLIA licensed laboratory.
  • When a patient serum sample is received by Siemens, it is tested using three high performance biomarker assays that are direct markers of active fibrosis
  • The results of the biomarkers are combined in an algorithm which generate the ELF score.
  • The ELF score has been shown to be a prognostic (predictive) indicator of a liver-related outcome occurring within 5 years in patients with liver disease related to fibrosis

If you have any questions about these studies, please email us at RenownIHI@renown.org and our research staff will contact you.